In silico investigation on the probable macromolecular drug targets involved in the anti-schizophrenia activity of Nardostachys jatamansi
DOI:
https://doi.org/10.1590/s2175-97902022e191134%20Keywords:
Schizophrenia, Nardostachys jatamansi, Dopamine, GABA, NMDAAbstract
Existing medications i.e. the antipsychotic drugs are known to be effective in treating only the positive symptoms of schizophrenia, while being ineffective on negative and cognitive symptoms of the disease. In addition, these medications cause extrapyramidal symptoms, forcing many patients towards natural medicine in the hope of minimizing the unwanted adverse effects. Nardostachys jatamansi is a medicinal plant that has been traditionally prescribed for various types of brain disorders. The active constituents of the plant have beneficial effects on the negative and cognitive symptoms of schizophrenia. This study was designed to identify the active constituents of Nardostachys jatamansi with the highest binding affinities for the key macromolecular drug targets involved in the pathophysiology of schizophrenia and thereby elucidate the possible mechanism of action. These targets are dopamine receptors, Gamma-aminobutyric acid receptors, N-methyl-D-aspartate receptors and Phosphodiesterase 10A. The results of molecular docking showed that, β-sitosterol, chlorogenic acid, oleanic acid and ursolic acid, displayed high binding affinity toward all the macromolecular drug targets. Ligands with steroid backbone and pentacyclic triterpene structure have been found to possess high binding affinity toward the dopamine receptor and phosphodiesterase 10A. While ligands with carbonyl group form stronger binding interactions with the N-methyl-D-aspartate receptor.
Downloads
References
ACD/ChemSketch Structure Elucidator, version 2018.1 ed. [computer program]. Advanced Chemistry Development, Inc., 2019.
Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry. 1982;39(7):784-788.
Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia: Methods, meanings, and mechanisms. Arch Gen Psychiatry. 1995;52(5):341-351.
Ballatore C, Huryn DM, Smith III AB. Carboxylic acid (bio) isosteres in drug design. ChemMedChem. 2013;8(3):385-395.
Banks WA. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol. 2009;9(Suppl 1):S3.
Barbee JG, Mancuso DM, Freed CR, Todorov AA. Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. Am J Psychiatry. 1992;149(8):1129.
BIOVIA DS. [computer program]. Discovery Studio Visualizer, 2016.
Chung D-w, Choi YT. Synthesis and solubility of hydrophilic derivatives of β-sitosterol. J Ind Eng Chem. 2007;13(3):367-372.
Crow T. Positive and negative schizophrenia symptoms and the role of dopamine. Br J Psychiatry. 1981;139(3):251-254.
Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S-i, Okumura K, et al. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem. 1999;274(26):18438-18445.
Hazra M, Noh S, Boon H, Taylor A, Moss K, Mamo DC. Complementary and alternative medicine in psychotic disorders. J Complementary Integr Med. 2010;7(1).
Hoenders HR, Bartels-Velthuis AA, Vollbehr NK, Bruggeman R, Knegtering H, de Jong JT. Natural medicines for psychotic disorders: a systematic review. J Nerv Ment Dis. 2018;206(2):81.
Kahn RS, Keefe RS. Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry. 2013;70(10):1107-1112.
Kalani MYS, Vaidehi N, Hall SE, Trabanino RJ, Freddolino PL, Kalani MA, et al. The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists. Proc National Acad Sci. 2004;101(11):3815-3820.
Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res. 2015;44(D1):D1202-D1213.
Mikitsh JL, Chacko A-M. Pathways for small molecule delivery to the central nervous system across the blood-brain barrier. Perspect Medicin Chem. 2014;6:PMC. S13384.
Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx. 2005;2(4):541-553.
Pandey MM, Katara A, Pandey G, Rastogi S, Rawat AK. An important Indian traditional drug of ayurveda jatamansi and its substitute bhootkeshi: chemical profiling and antioxidant activity. Evid Based Complement Alternat Med. 2013;2013:142517.
Patani GA, LaVoie EJ. Bioisosterism: A rational approach in drug design. Chem Rev. 1996;96(8):3147-3176.
Purnima BM, Kothiyal P. A review article on phytochemistry and pharmacological profiles of Nardostachys jatamansi DC-medicinal herb. J Pharmacogn Phytochem. 2015;3(5):102-106.
Romero-Hernandez A, Furukawa H. Novel mode of antagonist binding in NMDA receptors revealed by the crystal structure of the GluN1-GluN2A ligand-binding domain complexed to NVP-AAM077. Mol Pharmacol. 2017;92(1):22-29.
Thakur PK, Patre S, Pande R. Hydrogen-bond parameters and lipophilicity of hydroxamic acids: use in drug design. Int J Sci Res. 2014;3(9):1545-1548. https://www.ijsr.net/archive/v3i9/U0VQMTQ0NDc%3D.pdf
» https://www.ijsr.net/archive/v3i9/U0VQMTQ0NDc%3D.pdf
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455-461.
Verhoest PR, Chapin DS, Corman M, Fonseca K, Harms JF, Hou X, et al. Discovery of a novel class of phosphodiesterase 10a inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1 h-pyrazol-3-yl)-phenoxymethyl]-quinoline (pf-2545920) for the treatment of schizophrenia. J Med Chem. 2009;52(16):5188-5196.
Wang S, Che T, Levit A, Shoichet BK, Wacker D, Roth BL. Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature. 2018;555(7695):269-273.
Zhu S, Noviello CM, Teng J, Walsh RM, Kim JJ, Hibbs RE. Structure of a human synaptic GABA A receptor. Nature. 2018;559(7712):67-72.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
